Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2023 Mar 6

PMID 36874402

Authors

Ana M Metelo

Agnieszka Jozwik

Le Anh Luong

Delaney Dominey-Foy

Charlotte Graham

Charlotte Attwood

Shafqat Inam

Alan Dunlop

Katy Sanchez

Kirsty Cuthill

Carmel Rice

Matthew Streetly

Trevor Bentley

Bijan Boldajipour

Cesar Sommer

Barbra Sasu

Reuben Benjamin

Affiliations

Soon will be listed here.

Abstract

Significance: Multiple myeloma is an incurable cancer of the plasma cells. A new therapy with anti-BCMA CAR T cells - the patient's own T cells genetically engineered to find and kill myeloma cancer cells - has shown encouraging results. Unfortunately, patients still relapse. In this study, we propose to use T cells from HD volunteers, which have a stronger T-cell fitness, higher cancer killing capacity, and are ready to be administered when needed.

Citing Articles

Are we there yet? CAR-T therapy in multiple myeloma.

Mirvis E, Benjamin R Br J Haematol. 2024; 205(6):2175-2189.

PMID: 39558776 PMC: 11637742. DOI: 10.1111/bjh.19896.

Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma.

Testa U, Pelosi E, Castelli G Mediterr J Hematol Infect Dis. 2024; 16(1):e2024077.

PMID: 39534712 PMC: 11556426. DOI: 10.4084/MJHID.2024.077.

Bispecific antibody targets and therapies in multiple myeloma.

Rees M, Abdallah N, Yohannan B, Gonsalves W Front Immunol. 2024; 15:1424925.

PMID: 39450163 PMC: 11499143. DOI: 10.3389/fimmu.2024.1424925.

TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity.

Dharani S, Cho H, Fernandez J, Juillerat A, Valton J, Duchateau P Mol Ther. 2024; 32(11):3915-3931.

PMID: 39169622 PMC: 11573618. DOI: 10.1016/j.ymthe.2024.08.018.

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

Lin C, Tariq M, Ullah F, Sannareddy A, Khalid F, Abbas H Int J Mol Sci. 2024; 25(11).

PMID: 38892379 PMC: 11172591. DOI: 10.3390/ijms25116192.

References

Ahmed R, Gray D . Immunological memory and protective immunity: understanding their relation. Science. 1996; 272(5258):54-60. DOI: 10.1126/science.272.5258.54. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Nikolich-Zugich J . Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol. 2008; 8(7):512-22. PMC: 5573867. DOI: 10.1038/nri2318. View

Sommer C, Boldajipour B, Kuo T, Bentley T, Sutton J, Chen A . Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Mol Ther. 2019; 27(6):1126-1138. PMC: 6554542. DOI: 10.1016/j.ymthe.2019.04.001. View

Carpenter R, Evbuomwan M, Pittaluga S, Rose J, Raffeld M, Yang S . B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013; 19(8):2048-60. PMC: 3630268. DOI: 10.1158/1078-0432.CCR-12-2422. View

Ng L, Sutherland A, Newton R, Qian F, Cachero T, Scott M . B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004; 173(2):807-17. DOI: 10.4049/jimmunol.173.2.807. View

Puglisi F, Parrinello N, Giallongo C, Cambria D, Camiolo G, Bellofiore C . Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3. Int J Mol Sci. 2020; 20(14). PMC: 6678548. DOI: 10.3390/ijms20143548. View

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar O, Lucchini G . Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020; 396(10266):1885-1894. PMC: 11773457. DOI: 10.1016/S0140-6736(20)32334-5. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

10.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

11.

Eruslanov E, Bhojnagarwala P, Quatromoni J, Stephen T, Ranganathan A, Deshpande C . Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014; 124(12):5466-80. PMC: 4348966. DOI: 10.1172/JCI77053. View

12.

Graham C, Jozwik A, Pepper A, Benjamin R . Allogeneic CAR-T Cells: More than Ease of Access?. Cells. 2018; 7(10). PMC: 6210057. DOI: 10.3390/cells7100155. View

13.

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331. PMC: 5482103. DOI: 10.1182/blood-2017-02-769208. View

14.

Pont M, Hill T, Cole G, Abbott J, Kelliher J, Salter A . γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134(19):1585-1597. PMC: 6871311. DOI: 10.1182/blood.2019000050. View

15.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

16.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

17.

Parimi P, Birnkrant D, Rao L, Diaz G, Moore J . Effect of dexamethasone on lymphocyte subpopulations in premature infants with bronchopulmonary dysplasia. J Perinatol. 2000; 19(5):347-51. DOI: 10.1038/sj.jp.7200201. View

18.

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

19.

Guillerey C, Harjunpaa H, Carrie N, Kassem S, Teo T, Miles K . TIGIT immune checkpoint blockade restores CD8 T-cell immunity against multiple myeloma. Blood. 2018; 132(16):1689-1694. DOI: 10.1182/blood-2018-01-825265. View

20.

Rajan A, Rajkumar S . Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015; 5:e365. PMC: 4635200. DOI: 10.1038/bcj.2015.92. View